RxDoctor Payments Data

Joyce Valencia

Nurse Practitioner · San Jose, CANPI 1457892101

Payments from drug & device makers

$18,807in general payments, 2019–2025

Across 850 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Lilly USA, LLC$2K
  • Amgen$2K
  • AstraZeneca$1K
  • Xeris Pharmaceuticals, Inc.$1K
  • Mannkind Corporation$752
  • plus $8K from 45 others

What the payments were for

  • Food & beverage$18,741100%
  • Education$70%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,807 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide297$455,530
JardianceEmpagliflozin324$349,532
RybelsusSemaglutide171$210,112
TrulicityDulaglutide137$193,491
MounjaroTirzepatide120$160,227
KerendiaFinerenone88$95,790
Humalog Kwikpen U-200Insulin Lispro45$95,436
FarxigaDapagliflozin Propanediol71$77,345
Synjardy XrEmpagliflozin/Metformin Hcl78$74,565
Evenity (2 Syringes)Romosozumab-Aqqg21$51,718
JanuviaSitagliptin Phosphate41$51,444
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog56$40,255
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog38$40,143
Humalog Kwikpen U-100Insulin Lispro94$29,290
Tresiba Flextouch U-100Insulin Degludec37$26,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,076$665,642468 claims
Boehringer IngelheimJardiance, Synjardy Xr$643$424,097402 claims
Lilly USA, LLCTrulicity, Mounjaro, Lyumjev$2,390$356,997268 claims
BayerKerendia$746$95,79088 claims
AstraZenecaFarxiga$1,029$77,34571 claims
AmgenEvenity (2 Syringes)$2,130$51,71821 claims
MerckJanuvia$120$51,44441 claims
Johnson & JohnsonInvokamet$267$8,20214 claims
AbbVieSynthroid$173$1,98727 claims
Sanofi-aventis U.S. LLCLantus$638$1,84015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →